NIGHTHAWK BIOSCIENCES INC (NHWK) Fundamental Analysis & Valuation
NYSEARCA:NHWK • US42237K4094
Current stock price
0.4135 USD
+0.03 (+8.96%)
At close:
0.4299 USD
+0.02 (+3.97%)
After Hours:
This NHWK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. NHWK Profitability Analysis
1.1 Basic Checks
- NHWK had negative earnings in the past year.
- NHWK had a negative operating cash flow in the past year.
1.2 Ratios
- With a Return On Assets value of -74.32%, NHWK is not doing good in the industry: 71.89% of the companies in the same industry are doing better.
- NHWK's Return On Equity of -143.11% is on the low side compared to the rest of the industry. NHWK is outperformed by 65.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -74.32% | ||
| ROE | -143.11% | ||
| ROIC | N/A |
ROA(3y)-30.52%
ROA(5y)-42.03%
ROE(3y)-37.4%
ROE(5y)-62.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- NHWK's Gross Margin of 28.70% is fine compared to the rest of the industry. NHWK outperforms 76.43% of its industry peers.
- The Profit Margin and Operating Margin are not available for NHWK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.7% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. NHWK Health Analysis
2.1 Basic Checks
- NHWK does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, NHWK has more shares outstanding
- Compared to 1 year ago, NHWK has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -6.72, we must say that NHWK is in the distress zone and has some risk of bankruptcy.
- NHWK has a Altman-Z score of -6.72. This is in the lower half of the industry: NHWK underperforms 72.22% of its industry peers.
- NHWK has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.25, NHWK is doing worse than 71.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.72 |
ROIC/WACCN/A
WACC10.89%
2.3 Liquidity
- A Current Ratio of 0.99 indicates that NHWK may have some problems paying its short term obligations.
- NHWK's Current ratio of 0.99 is on the low side compared to the rest of the industry. NHWK is outperformed by 90.40% of its industry peers.
- A Quick Ratio of 0.99 indicates that NHWK may have some problems paying its short term obligations.
- With a Quick ratio value of 0.99, NHWK is not doing good in the industry: 89.23% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.99 |
3. NHWK Growth Analysis
3.1 Past
- The earnings per share for NHWK have decreased strongly by -21.47% in the last year.
- NHWK shows a strong growth in Revenue. In the last year, the Revenue has grown by 147.78%.
- The Revenue has been growing by 33.23% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-21.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
Revenue 1Y (TTM)147.78%
Revenue growth 3Y27.89%
Revenue growth 5Y33.23%
Sales Q2Q%1100%
3.2 Future
- The Earnings Per Share is expected to grow by 18.45% on average over the next years. This is quite good.
- The Revenue is expected to grow by 71.98% on average over the next years. This is a very strong growth
EPS Next Y-16.18%
EPS Next 2Y23.97%
EPS Next 3Y18.45%
EPS Next 5YN/A
Revenue Next Year-28.99%
Revenue Next 2Y72.79%
Revenue Next 3Y71.98%
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. NHWK Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for NHWK. In the last year negative earnings were reported.
- Also next year NHWK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as NHWK's earnings are expected to grow with 18.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.97%
EPS Next 3Y18.45%
5. NHWK Dividend Analysis
5.1 Amount
- NHWK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NHWK Fundamentals: All Metrics, Ratios and Statistics
0.4135
+0.03 (+8.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20 2023-11-20/amc
Earnings (Next)03-29 2024-03-29/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap36.34M
Revenue(TTM)2.23M
Net Income(TTM)-51.95M
Analysts43.33
Price Target10.2 (2366.75%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.76%
Min EPS beat(2)-40.06%
Max EPS beat(2)-15.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.5%
Min Revenue beat(2)-55.88%
Max Revenue beat(2)26.87%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 16.3 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1 | ||
| P/tB | 1 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.98
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.03
BVpS0.41
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -74.32% | ||
| ROE | -143.11% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.7% | ||
| FCFM | N/A |
ROA(3y)-30.52%
ROA(5y)-42.03%
ROE(3y)-37.4%
ROE(5y)-62.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 43.83% | ||
| Cap/Sales | 121.08% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | -6.72 |
F-Score3
WACC10.89%
ROIC/WACCN/A
Cap/Depr(3y)351.08%
Cap/Depr(5y)283.29%
Cap/Sales(3y)138.98%
Cap/Sales(5y)87.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
EPS Next Y-16.18%
EPS Next 2Y23.97%
EPS Next 3Y18.45%
EPS Next 5YN/A
Revenue 1Y (TTM)147.78%
Revenue growth 3Y27.89%
Revenue growth 5Y33.23%
Sales Q2Q%1100%
Revenue Next Year-28.99%
Revenue Next 2Y72.79%
Revenue Next 3Y71.98%
Revenue Next 5YN/A
EBIT growth 1Y-45.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.4%
OCF growth 3YN/A
OCF growth 5YN/A
NIGHTHAWK BIOSCIENCES INC / NHWK Fundamental Analysis FAQ
What is the ChartMill fundamental rating of NIGHTHAWK BIOSCIENCES INC (NHWK) stock?
ChartMill assigns a fundamental rating of 2 / 10 to NHWK.
What is the valuation status for NHWK stock?
ChartMill assigns a valuation rating of 0 / 10 to NIGHTHAWK BIOSCIENCES INC (NHWK). This can be considered as Overvalued.
How profitable is NIGHTHAWK BIOSCIENCES INC (NHWK) stock?
NIGHTHAWK BIOSCIENCES INC (NHWK) has a profitability rating of 1 / 10.
What is the financial health of NIGHTHAWK BIOSCIENCES INC (NHWK) stock?
The financial health rating of NIGHTHAWK BIOSCIENCES INC (NHWK) is 0 / 10.